Last reviewed 2026-04-20 · How we verify

Xanthomycin A (GUAMECYCLINE)

Phase 2 active Small molecule

Xanthomycin A (generic name: GUAMECYCLINE) is a guamecycline drug. It is currently in Phase 2 development.

Xanthomycin A is a small molecule that works by binding to a specific target, although the exact target is unknown.

Xanthomycin A, also known as guamecycline, is a small molecule drug of unknown target and class. Its development and current ownership are not specified, and it has not been approved by the FDA for any indications. The drug's pharmacokinetic properties, such as half-life and bioavailability, are also unknown. Xanthomycin A's commercial status, including patent status and generic availability, is unclear. As a result, key safety considerations and potential side effects are not well established.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	GUAMECYCLINE
Drug class	guamecycline
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and Xanthomycin A is a key that fits into one of those locks. When it binds, it can either unlock or block the normal functioning of the cell, depending on the target and the specific effects of the drug. This can help to treat certain diseases by altering the behavior of cells in the body.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Xanthomycin A CI brief — competitive landscape report
Xanthomycin A updates RSS · CI watch RSS

Frequently asked questions about Xanthomycin A

What is Xanthomycin A?

Xanthomycin A (GUAMECYCLINE) is a guamecycline drug.

How does Xanthomycin A work?

Xanthomycin A is a small molecule that works by binding to a specific target, although the exact target is unknown.

What is the generic name of Xanthomycin A?

GUAMECYCLINE is the generic (nonproprietary) name of Xanthomycin A.

What drug class is Xanthomycin A in?

Xanthomycin A belongs to the guamecycline class. See all guamecycline drugs at /class/guamecycline.

What development phase is Xanthomycin A in?

Xanthomycin A is in Phase 2.

Drug class: All guamecycline drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing